- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02443753
EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
A Pilot Safety and Tolerability Study of the Use of the EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
This study will be conducted at a single clinical site in Malaysia. Approximately 16 subjects will be enrolled in two cohorts of 8 subjects. The two cohorts will be implanted one week apart with the implantation of the second cohort triggered by the absence of major technical or clinical issues (i.e. safety, tolerability) observed in the first cohort in the first seven days.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
-
Kuala Lumpur, Malaysia, 50603
- Universiti Malaya Medical Centre, Jalan universiti
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age > 21 years and < 65 years - male or female
- Overweight or obese individuals (BMI ≥ 27 kg/m2 and ≤ 40 kg/m2)
- Diagnosed with Type 2 diabetes and being treated by diet or oral agents (metformin, SU, DPP-4i, or TZD)
- Glycemic state: HbA1c at screening 7.0-10.0%.
- History of failure with non-surgical weight loss methods
- Subjects willing to comply with study requirements
- Subjects who have signed an informed consent form
Exclusion Criteria:
Diabetic subjects requiring injectable treatments (insulin, GLP-1R agonists)
- Subjects requiring anticoagulation therapy
- Subjects with iron deficiency and iron deficiency anemia
- Condition of the gastrointestinal tract, such as ulcers or inflammatory bowel disease
- Treatment represents an unreasonable risk to the subject
- Known history of acute or chronic pancreatitis
- Known history of organ failure (i.e. renal insufficiency, heart failure, fibrotic / cirrhotic liver disease, or pulmonary disease)
- Symptomatic coronary artery disease or pulmonary dysfunction
- Subjects with known symptomatic biliary disease
- Known infection at the time of implant
- Severe coagulopathy, upper gastro-intestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasia
- Congenital or acquired anomalies of the GI tract such as atresias or stenoses
- Pregnant or has the intention of becoming pregnant in the next 6 months
- Unresolved alcohol or drug addiction
- HIV positive subjects
- Subjects with hepatitis B or C
- Currently taking the following medications within 30 days of implant:
systemic corticosteroids, drugs known to affect GI motility, prescription or over the counter weight loss medications such as Sibutramine hydrochloride monohydrate and Orlistat
- Allergy or hypersensitivity to ceftriaxone, cephalosporins, penicillin, and all equivalent antibiotics
- Any characteristics which, in the opinion of the investigator, makes the subject a poor candidate for device placement in this clinical trial
- Previous GI surgery that could affect the ability to place the liner or the function of the implant.
- Subjects unable to discontinue NSAIDs (non-steroidal anti-inflammatory drugs) during the implant period
- H. pylori positive subjects (Note: patients may be enrolled if they had a prior history and were successfully treated).
- Family or subject history of a known diagnosis or pre-existing symptoms of systemic lupus erythematosus, scleroderma or other autoimmune connective tissue disorder
- Unable to tolerate proton pump inhibitors
- Participating in another ongoing investigational clinical trial that is ongoing or within 3 months of the implant date
- Positive stool guaiac at time of screening
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Device
Subjects who receive the device
|
Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months.
The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis.
The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Safety and Tolerability will be evaluated as the incidence of AEs and SAEs/UADEs.
Tidsramme: 3 months
|
Safety will be evaluated as the incidence of AEs and SAEs/UADEs.
|
3 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Efficacy as measured by Change in Body weight
Tidsramme: 3 months
|
Change in Body weight
|
3 months
|
Efficacy as measured by Percent excess weight loss
Tidsramme: 3 months
|
Percent excess weight loss
|
3 months
|
Efficacy as measured by Change in HbA1c (%)
Tidsramme: 3 months
|
Change in HbA1c (%)
|
3 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Eng Hong Pok, MD, University of Malaya
- Ledende efterforsker: Wah Kheong Chan, MD, University of Malaya
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 15-1
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med EndoBarrier SANS
-
Bausch Health Americas, Inc.AfsluttetRheumatoid arthritisForenede Stater
-
Chung Shan Medical UniversityAfsluttet
-
Fourth Affiliated Hospital of Guangxi Medical UniversityLiuzhou Maternity and Child Healthcare Hospital; Liuzhou Hospital of Traditional...Ukendt
-
Seoul National University HospitalAfsluttetBrystkræft | Vaginal atrofiKorea, Republikken
-
University of California, San FranciscoAfsluttet
-
The University of Hong KongThe Research Fund for the Control of Infectious Diseases of the Food...AfsluttetAkutte øvre luftvejsinfektionerKina
-
Committee on Chinese Medicine and PharmacyAfsluttet
-
Chan-Yong JeonKyung Hee University Hospital at Gangdong; Kyunghee University Medical... og andre samarbejdspartnereAfsluttetForkølelsesoverfølsomhedKorea, Republikken
-
Yu-Ching HSUAfsluttetSøvnløshed, kinesiske urter, Xiao-Yao-San, polysomnografiTaiwan
-
Albert Einstein College of MedicineAfsluttet